The pre-formed and radiopaque flex hydrogel spacer is now FDA approved and will begin limited distribution in the US. The US Food and Drug Administration (FDA) has granted 510 (k) clearance for ...

Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians ...

Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver ...

Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging. Melbourne (Australia) and Indianapolis, IN (United States) \| September 30, 2026. FDA Fast T ...

“It should be protocol that 100% of your patients with metastatic prostate cancer get germline testing. Full stop. No exceptions,” said Neal D. Shore, MD, FACS.

A phase III trial ancillary analysis found the Decipher Prostate Test predicts which intermediate-risk prostate cancer ...

First predictive evidence in intermediate-risk prostate cancer supporting use of the Decipher test to guide short-term hormone therapy decisions to be presented at ASTRO 2026. SOU ...

There is a moment in a prostate cancer consultation when I sometimes wish I could slow time down. The patient has already been through the blood test, the scan and ...

Stereotactic body radiation therapy significantly improved quality of life outcomes, including urinary incontinence and ...

The FDA cleared the SpaceOAR Flex System, a hydrogel spacer used during prostate cancer radiotherapy, in a 510 (k) supported by the HYDROSPACE trial.

When David Brown learned he had prostate cancer at 48, survival was not his only concern. A husband, father, and businessman, ...

NRG-GU005: SBRT vs Moderately Hypofractionated IMRT in Localized Prostate Cancer / cancer, cancer care, Cancer research, cancer treatment, clinical trials, ...